Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gnanesh Patel

Rheumatology Wilkes Barre, PA Medical Doctor

NPI 1316238298 CMS profile 196085

150 Mundy St, Arthritis Center Of Nepa, Wilkes Barre, PA 18702

Open in the dashboard

General payments

$48,946

994 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gnanesh Patel of Wilkes Barre, PA is reported in the CMS Open Payments database as having received $48,946 across 994 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,857 168
2024 General $2,682 151
2023 General $2,390 121
2022 General $2,198 123
2021 General $3,284 94
2020 General $4,418 61
2019 General $31,117 276

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gnanesh Patel
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Gnanesh Patel were reported at $2,857. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Gnanesh Patel Rheumatology median Middle half National median
2019 $31,117 $744 $153–$2,687 $163
2020 $4,418 $462 $98–$2,027 $114
2021 $3,284 $531 $101–$2,153 $132
2022 $2,198 $627 $125–$2,303 $149
2023 $2,390 $741 $145–$2,524 $160
2024 $2,682 $830 $166–$2,660 $164
2025 $2,857 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $25,459 180 payments
  2. UCB, Inc. $11,479 111 payments
  3. Amgen Inc. $2,583 180 payments
  4. Janssen Biotech, Inc. $2,420 109 payments
  5. Novartis Pharmaceuticals Corporation $1,119 78 payments
  6. Radius Health, Inc. $732 54 payments
  7. Pfizer Inc. $642 65 payments
  8. AstraZeneca Pharmaceuticals LP $637 31 payments
  9. GlaxoSmithKline, LLC. $447 22 payments
  10. Janssen Scientific Affairs, LLC $409 6 payments
  11. Other $3,019 158 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,738 17 payments
  2. Food and Beverage $17,236 954 payments
  3. Consulting Fee $6,750 1 payment
  4. Travel and Lodging $3,929 11 payments
  5. Education $293 11 payments
Products named General payments · program years 2019–2025
  1. RINVOQ Immunology $14,676 93 payments
  2. Cimzia $11,149 86 payments
  3. HUMIRA $4,324 30 payments
  4. RINVOQ Immunology $3,611 8 payments
  5. SIMPONI ARIA $1,565 65 payments
  6. TREMFYA $1,371 58 payments
  7. STELARA $1,195 43 payments
  8. Prolia $918 70 payments
  9. EVENITY $852 61 payments
  10. SAPHNELO $592 28 payments
  11. Other $10,477 646 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

3,052

Median for Rheumatology: 1,511

Drug cost

$841,305

Median for Rheumatology: $1,139,948

Branded share of claims

35.5%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 42 $330,054
Enbrel Etanercept Brand 19 $137,861
Prolia Denosumab Brand 74 $126,559
Cimzia (2 Pack) Certolizumab Pegol Brand 21 $119,900
Orencia Abatacept Brand 13 $72,352
Methotrexate Methotrexate Sodium Brand 901 $22,370
Hydroxychloroquine Sulfate Generic 786 $19,268
Leflunomide Generic 109 $4,802
Prednisone Generic 608 $2,842
Allopurinol Generic 166 $1,756

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$3,356,346

Of which drugs: $3,073,955

Medicare patients

780

Average age 76

Services billed

303,690

592 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 53%
Ischemic heart disease 31%
Diabetes 24%
Chronic kidney disease 21%
Atrial fibrillation 18%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 37 29,625 $1,002,092
Injection, golimumab, 1 mg, for intravenous use J1602 Office 72 75,096 $682,202
Injection, denosumab, 1 mg J0897 Office 260 26,820 $547,321
Injection, tocilizumab, 1 mg J3262 Office 14 73,571 $346,071
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 19 83,600 $301,294
Injection, zoledronic acid, 1 mg J3489 Office 17 85 $442
Infusion, normal saline solution, 250 cc J7050 Office 100 138 $72

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$425 — —
Cimzia
$243 21 83,600
RINVOQ
$200 — —
COSENTYX
$195 — —
Tymlos
$167 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

994 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record